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Abstract: Pediatric (PARDS) and neonatal (NARDS) acute respiratory distress syndrome  have different age‑specific 
characteristics and definitions. Trials on surfactant for ARDS in children and neonates have been performed well 
before the PARDS and NARDS definitions and yielded conflicting results. This is mainly due to heterogeneity in study 
design reflecting historic lack of pathobiology knowledge. We reviewed the available clinical and preclinical data to 
create an expert consensus aiming to inform future research steps and advance the knowledge in this area. Eight trials 
investigated the use of surfactant for ARDS in children and ten in neonates, respectively. There were improvements in 
oxygenation (7/8 trials in children, 7/10 in neonates) and mortality (3/8 trials in children, 1/10 in neonates) improved. 
Trials were heterogeneous for patients’ characteristics, surfactant type and administration strategy. Key pathobiologi‑
cal concepts were missed in study design. Consensus with strong agreement was reached on four statements:
1. There are sufficient preclinical and clinical data to support targeted research on surfactant therapies for PARDS 
and NARDS. Studies should be performed according to the currently available definitions and considering 
recent pathobiology knowledge.
2. PARDS and NARDS should be considered as syndromes and should be pre-clinically studied according to key 
characteristics, such as direct or indirect (primary or secondary) nature, clinical severity, infectious or non-
infectious origin or patients’ age.
3. Explanatory should be preferred over pragmatic design for future trials on PARDS and NARDS.
4. Different clinical outcomes need to be chosen for PARDS and NARDS, according to the trial phase and design, 
trigger type, severity class and/or surfactant treatment policy.
We advocate for further well‑designed preclinical and clinical studies to investigate the use of surfactant for PARDS 
and NARDS following these principles.
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Background
Acute respiratory distress syndrome (ARDS) occurs 
at any age including pediatric (PARDS) and neonatal 
(NARDS) patients, and age-specific definitions of the syn-
drome are now available, namely the pediatric acute lung 
injury consensus conference (PALICC) and the Mon-
treux definition for PARDS and NARDS, respectively [1, 
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2]. PALICC and Montreux definitions should be used, 
respectively, for children beyond the first month of age 
and for neonates from birth until 4  weeks, or 44  weeks 
post-menstrual age if born before 40-weeks’ gestation 
(Additional file 1) [3]. ARDS is  a life-threatening respira-
tory failure characterized by lung tissue inflammation [4] 
and alveolar and/or endothelial damage [5] coupled with 
a complex surfactant injury [6]. In children and neo-
nates, these features may translate in different epidemiol-
ogy, triggers and clinical approach [1, 7, 8]. For example, 
direct or pulmonary (primary) and indirect or extrapul-
monary (secondary) ARDS may have peculiar triggers 
in children and neonates, such as meconium aspiration, 
bronchiolitis or necrotizing enterocolitis. Lung tissue in 
children is less prone to inflammation and fibrosis, while 
the relative volume is smaller as the alveolarization is still 
ongoing [9]. Endogenous surfactant is present in rela-
tively higher concentrations, and similarly, higher doses 
of exogenous surfactant are more easily administered [9].
Despite these peculiarities, ARDS pathobiology pattern 
(inflammation, cellular damage and surfactant dysfunc-
tion) is the same in patients of any age. Inflammation and 
cellular damage also contribute to surfactant qualitative 
and quantitative injury, affecting both surfactant proteins 
and phospholipids [10]. From a molecular point of view, 
phospholipases, proteases, inflammatory mediators and 
oxygen reactive species play a role in this damage [3, 7]. 
Once the injury has been triggered, a vicious cycle drives 
ARDS: (1) phospholipase-driven surfactant phospho-
lipid hydrolysis; (2) production of free fatty acids; and (3) 
derived inflammatory mediators; (4) further surfactant 
damage due to inflammatory mediators [12]. This ‘sur-
factant catabolism-inflammation-surfactant catabolism’ 
mechanism can perpetuate the injury and worsen the loss 
of alveolar-capillary barrier function. This, in its turn, 
facilitates the  cellular  influx toward the lung and the 
accumulation of proteins within the interstitial and alve-
olar space. Neutrophils and alveolar macrophages may 
increase the local inflammation, worsening the vicious 
cycle. In fact, in  vivo studies on adult ARDS patients 
showed that disaturated phosphatidylcholine turnover is 
faster compared to controls, due to increased surfactant 
catabolism [13]. These mechanisms represent the ‘exuda-
tive phase’ of ARDS. They cause an increase in alveolar 
surface tension and a reduction in lung compliance. This 
pathobiology is known to be different between direct and 
indirect ARDS as the two types of the syndrome have 
distinct cellular and biochemical injury profile [14–16]. 
Data in pediatric patients are more limited but consistent 
and also indicated differences between ARDS of infec-
tious or non-infectious origin [17]. Later, in the severest 
cases, the picture may eventually evolve into the ‘fibro-
proliferative phase’ characterized by the formation of 
hyaline membranes, influx of proliferating mesenchymal 
cells, epithelial cell necrosis/apoptosis, thrombogenesis 
in pulmonary vessels and lung fibrosis. This phase may 
occur within 3–4 days of injury in some parts of the lung 
and can overlap with the exudative phase in other parts 
of the lung. Given this pathobiology, it is not surprising 
that surfactant has been considered a potential thera-
peutic agent for the early phase of ARDS, to reverse the 
surfactant dysfunction, improve compliance and (re-)
open the alveoli, allowing better gas exchange and/or less 
aggressive respiratory support.
So far, attempts to cure ARDS with surfactant have not 
led to impressive results. This was likely due to many rea-
sons such as: 1) lack of efficient alveolar surfactant deliv-
ery; 2) inactivation of surfactant by phospholipase A2 
and other surfactant-injuring agents; 3) insufficient dose; 
4) wrongful trial design. This latter may be due to several 
issues, but undoubtedly a main one is represented by lack 
of homogeneity as trials included very different patients, 
types of ARDS, surfactant preparations, comorbidities 
and co-interventions [18]. There is effort to find ‘enrich-
ment tools’ (such as biomarkers or imaging techniques) 
to better describe ARDS populations in adult critical care 
[19], and this is definitively needed for patients of any 
age.
Several studies on the use of surfactant for ARDS in 
children and neonates have been published. Nonethe-
less, despite the pediatric/neonatal experience being 
wider than that of adult medicine, evidence in favor of 
surfactant is still unavailable [20]. We aim to analyze data 
to offer an expert consensus opinion suggesting how to 
advance the knowledge in pediatric (PARDS) and neona-
tal (NARDS) ARDS field.
Methods
We planned to perform a narrative review about sur-
factant for ARDS in children and neonates, and based on 
this, to create a consensus opinion about future research 
steps in this field. The European Society for Pediat-
ric and Neonatal Intensive Care (ESPNIC) created an 
expert committee, including two intensivists skilled in 
relevant methodology, as in previous ESPNIC guidelines 
[21]. The project was divided into two phases: (1) review 
of the literature and (2) production of expert consensus 
opinion. Since well-known trials’ heterogeneities prevent 
data aggregation [20], we did not perform any quantita-
tive meta-analysis or bias assessment. This is consistent 
with our aim which was not to give any advice on clinical 
efficacy. We focused: on (1) any translational or animal 
study on surfactant biology during ARDS and (2) rand-
omized controlled trials comparing surfactant therapy 
versus standard care for ARDS in children and neonates, 
irrespective of definition used to diagnose the syndrome. 
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We decided so because PARDS and NARDS definition 
are quite recent; thus, many clinical studies had to be 
based on different entry criteria. Studies about the first-
generation, protein-free surfactants have been excluded 
as they are no longer marketed and were not used in 
ARDS trials. These surfactants are clinically inferior to 
animal surfactant preparations, which contain higher 
amount of proteins, in preterm neonates with respiratory 
distress syndrome (RDS, i.e., hyaline membrane disease 
due to primary surfactant deficiency) [22]. Moreover, 
ARDS patients also show decreased levels of surfactant 
proteins; thus, protein-free surfactants are likely to be 
less efficacious to treat ARDS, as well [23]. Quaker-based 
technique [24] was used for panel discussion, and recom-
mendations were voted as in previous ESPNIC guidelines 
[21]. Panel composition, literature review and consensus 
methodology are detailed in Additional file 2.
Results
Literature review
Additional file  3 reports the basic data of clinical trials 
included in the review. Trials were very heterogeneous 
for patients’ age, type of ARDS, entry criteria and case 
mix, surfactant type, dose and administration technique, 
injected volume and ventilatory policy. These are main 
points that may have prevented to have solid results. In 
particular, patients’ age was especially variable in pediat-
ric trials, with one expanding enrolment beyond pediatric 
age (including patients with malignances up to 25 years 
old) [25]. Ventilatory strategy is also variable and, notably, 
often not protocolized and left to the decision of attend-
ing physicians in neonatal trials. Table  1 summarizes 
the characteristics of surfactant preparations trialed for 
ARDS in children and neonates as bolus administration 
or broncho-alveolar lavage. Six natural and one synthetic 
surfactant have been used. Animal-derived surfactants 
were either bovine or porcine and produced with various 
techniques. Surfactant preparations have extremely vari-
able phospholipid profile and protein concentrations 
[26]. The synthetic surfactant (lucinactant) contains a 
synthetic peptide  (KL4 or sinapultide) designed to mimic 
the sequence pattern of amphipathic helix of SP-B. 
Sinapultide is a 21-amino-acid hydrophobic synthetic 
peptide consisting of four leucine (L) and a lysine (K) 
repeating units. Moreover, it has a simple phospholipid 
profile, consisting of only dipalmitoylphosphatidylcho-
line, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol 
and palmitic acid.
Tables 2 and 3 summarize the review results: eight and 
ten trials investigated the use of surfactant for ARDS in 
children [25, 27–33] and neonates [34–43], respectively. 
Notably, one manuscript was not considered because it 
was a subgroup post hoc analysis of another trial [44].
None of the pediatric trials used the PALICC definition 
specific to PARDS [2]. Surfactant improved oxygenation 
in almost all these trials [25, 27–33], and mortality was 
lowered in 3 out of 8 trials [28–30]; other respiratory out-
comes were also often ameliorated. Biochemical and bio-
physical parameters were not studied.
The Montreux definition of NARDS was released in 
2017 and only one trial used it [43]. All the other neonatal 
trials enrolled patients with respiratory disorders appear-
ing as NARDS but defined with variable criteria. Only 
one trial provided mortality data and showed improve-
ment [41], and only one provided some biological or bio-
physical results [34]. Surfactant improved oxygenation in 
the 7 out of 10 trials [35, 37–40, 40–43]. Other outcomes 
were ameliorated in 6 trials [34–36, 38, 41, 42].
Expert consensus
The following statements were approved:
1. There are sufficient preclinical and clinical data to 
support targeted research on surfactant therapies for 
Table 1 Characteristics of surfactants trialed for ARDS, in children and neonates as bolus and/or broncho-alveolar lavage
Abbreviations: PL: phospholipids




Beractant Abbvie USA Bovine Minced lung 25 Yes Yes
Bovactant Boehringer Ingelheim Pharma Germany Bovine Lung lavage 45 Yes No




CR Double Crane China Bovine (calf ) Lung lavage 30 No Yes
Lucinactant Discovery Lab USA Chemical Synthetic 30 Yes No
Poractant‑α Chiesi Farmaceutici Italy Porcine Modified minced lung 80 Yes Yes
Surface CENSA Cuba Porcine Lung lavage 25 Yes No
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Table 2 Synthesis of results: surfactant therapy in children
Boxes were colored in green or red if, for a given outcome, the surfactant treatment had a positive effect or not, respectively. Boxes were left blank where no data were 
available. No studies reported any biochemical or biophysical parameter
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PARDS and NARDS. Studies should be performed 
according to the currently available PARDS and 
NARDS definitions and considering the more recent 
knowledge on ARDS pathobiology (strong agree-
ment).
Nowadays, the availability of appropriate clinical defi-
nitions for PARDS and NARDS [1, 2] (Additional file 1) 
represents an important step forward to improve ARDS 
care and recognizes that differences exist between 
patients of various ages and severity. Few trials have used 
these definitions, and their implementation is urgently 
warranted. Although both the PALICC and the Berlin 
[45] definitions could be used for adolescents or young 
adults [3], it is advisable to prefer the pediatric definition 
to allow further comparison and data aggregation [3]. 
Some neonatal respiratory disorders that may appear as 
NARDS have been variously defined before the release 
of the Montreux definition of NARDS [1]. Nonetheless, 
pathophysiology and biology are shared between these 
disorders and the use of an unique definition can speed 
up research and development of surfactant therapies 
for a wider number of patients [1]. Knowledge of ARDS 
and surfactant pathobiology has significantly advanced 
during recent years, and new concepts have been intro-
duced, such as the role of secretory phospholipase A2 
enzymes in the surfactant catabolism [11, 46], the vicious 
cycle connecting surfactant catabolism and inflammation 
[17], the deficiency and injury of surfactant proteins [23, 
47], the variable cellular injury in direct (primary) and 
indirect (secondary) ARDS [14, 16] and the lower sus-
ceptibility of infant and juvenile compared to adult lung 
tissue [9]. These concepts should be taken into account in 
future trial design.
2. PARDS and NARDS should be considered as syn-
dromes and should be preclinically studied accord-
ing to key characteristics, such as direct (primary) or 
indirect (secondary) nature, clinical severity, infec-
tious or non-infectious origin or patients’ age (strong 
agreement).
Several NARDS and PARDS experimental models 
are available to mimic these characteristics [48–51], 
but results of preclinical investigations cannot have the 
same value for all patients, since subtypes of PARDS and 
NARDS show relevant differences in pathobiology and 
pathophysiology. Several factors should be considered in 
pre-clinical models: trigger, animal size and the degree of 
lung development (i.e., patients’ age), presence of immu-
nodeficiency or comorbidities, as well as the initial sever-
ity and the ventilatory strategy [1, 8, 52]. Unfortunately, 
the need of different preclinical model to mimic differ-
ent clinical situations has often gone unnoticed and may 
have negatively influenced the perception of research 
results. Accumulating data show that these factors signif-
icantly influence the clinical course and outcomes: thus 
it is important to consider them before starting a clinical 
trial [14, 16, 17, 53–55]. Lung size and the volume avail-
able for aeration are also important as they will influence 
surfactant volume of distribution, the actual alveolar 
delivery and consequently the optimal dose and admin-
istration method [56]. The type of surfactant prepara-
tion and its concentration must also be considered since 
the administered volume may significantly influence the 
amount of phospholipids actually reaching the alveoli 
[56]. For these reasons, there is a clear need of transla-
tional studies focused on at least some of these factors 
[57]. In this context, studies aiming to clarify the optimal 
surfactant concentration and dose to be administered are 
urgently needed.
2. Explanatory should be preferred over pragmatic 
design for future clinical trials on PARDS and 
NARDS (strong agreement).
This is the direct clinical counterpart of the previous 
point. ARDS is a very heterogeneous syndrome with vari-
ous origins, presentations, severity, comorbidities and co-
interventions. Trials enrolling broad groups of patients 
mixing all these factors are called pragmatic and seek a 
‘real-world’ answer regarding an established interven-
tion or refinement of current care [58]. This is not the 
case of surfactant and ARDS, since surfactant therapies 
are not yet standard of care for NARDS and PARDS 
and may represent a major improvement, rather than a 
minor refinement. Furthermore, although surfactant has 
a strong preclinical background suggesting its usefulness 
in ARDS, several concomitant clinical factors could influ-
ence response to treatment and outcomes [14, 16, 17, 53–
55]. Patients’ age, type of ARDS, comorbidities, timing of 
the intervention, type and dose of surfactant, ventilatory 
policy and cointerventions are examples of the factors 
potentially important to stratify for. Trials with a highly 
† Trend which does not reach significance threshold
°A further article is not considered, since it was a post hoc analysis of a subgroup enrolled in one of these trials [44]
* This trial investigated the administration of surfactant following recruitment maneuver versus standard care
Abbreviations: MOFS: multi-organ failure syndrome; PICU: pediatric intensive care unit
Table 2 (continued)
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Table 3 Synthesis of results: surfactant therapies in neonates
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specific selection or stratification are called explanatory 
and are more suitable and likely to provide significant 
results, although they are more complex and long-lasting 
[58]. There are at least 10 items to be considered in order 
to evaluate the pragmatism of a trial design [59]. Thus, 
future clinical trials should be as more explanatory as 
possible and focus on homogeneous groups of patients, 
according to the recently accumulated knowledge. In the 
UK, such trials are termed ‘efficacy and mechanism eval-
uation studies’ as they allow experimental mechanism 
evaluation that is unhindered by predefined trial out-
come measures [60]. The choice of an explanatory design 
reflects the complexity of PARDS and NARDS, the need 
to consider them as multifaceted syndromes and to 
learn from correspondent preclinical models. When it 
comes to PARDS, patients’ age should also be restricted 
as much as possible, as it may significantly influence sur-
factant pharmacology and susceptibility to lung injury 
[9]. It is interesting to note that ventilation is the main 
co-intervention in these trials and was extremely variable 
and even non-protocolized in neonatal trials. This signif-
icantly reduces the trial quality and may have hindered 
the possibility to detect any effect of surfactant therapy.
A next step for a correct trial design would be a for-
mal post hoc analysis of available data trying to identify 
which type of patients and ARDS should be the more 
likely to benefit from surfactant or which surfactant 
preparation should be preferred. According to a similar 
post hoc analysis of clinical trials conducted in adults 
[61] and to the recent knowledge on ARDS pathobiol-
ogy and pharmacology [62], direct (primary) ARDS is 
more likely to benefit from surfactant treatments. In 
the future, we can imagine an even more individualized 
therapy by using genomic approaches or biomarkers 
of ARDS severity and type: the surfactant adsorption 
test [63–65] and the surfactant protein-D assay [66, 67] 
are two of the most advanced tools in this field. These, 
and other that may eventually come, can open the way 
for a precision medicine approach to ARDS surfactant 
therapy, as it is proposed in similar fields [68]. From a 
pharmacological point of view, preferably, an enhanced 
surfactant more resistant to phospholipase and 
inactivation has higher chances to be beneficial. A more 
concentrated surfactant seems also preferable, but the 
ideal dose and administration technique as well as the 
best strategy to spread it and increase alveolar delivery 
are still unknown and require specific studies.
4. Different clinical outcomes need to be chosen for 
PARDS and NARDS, according to the trial phase 
and design, type of trigger, severity class and/or sur-
factant treatment policy (strong agreement).
In general, trials must be conducted taking into 
consideration the most recent epidemiological data 
and a combination of clinically meaningful short- and 
long-term outcomes. For instance, it would be illogi-
cal to have mortality as a short-term outcome for mild 
PARDS or NARDS, as these are already subjected to 
relatively low mortality, while oxygenation, physiol-
ogy parameters and burden of care measures are more 
suitable. As long-term outcomes, respiratory function 
measures may be preferred over pediatric quality of 
life measures which may be influenced by several other 
confounders [69].
Pathophysiological and biological plausibility is 
extremely important. Researchers should give prior-
ity to outcomes with a known direct pathophysiological 
link with the syndrome (such as short-term mortality, 
ventilator-free days and indices of gas exchange or oxy-
genation) [70–72]. Conversely, clinical endpoints that do 
not have a direct and clear connection with PARDS or 
NARDS should not be considered as primary outcomes. 
For instance, preterm neonates affected by NARDS may 
have negative long-term outcomes related to prematurity 
rather than to NARDS itself. Similarly, PARDS patients 
with malignancies may have a number of complications 
and negative outcomes because of their underlying dis-
ease rather than PARDS itself. Need for extracorporeal 
life support should only be considered if homogeneously 
available and defined in each recruiting center.
Finally, not only endpoints, but also the trajectory of 
disease should be considered in trial design. There are 
Table 3 (continued)
Boxes were colored in green or red if, for a given outcome, the surfactant treatment had a positive effect or none, respectively. Boxes were left blank where no data 
were available
# This study enrolled a mixed population of NARDS induced by meconium aspiration or sepsis but also non-ARDS conditions such as RDS or idiopathic persistent 
pulmonary hypertension of the neonate
† Same results with other oxygenation metrics; results obtained with up to 3 surfactant doses
* Trend which does not reach significance threshold. #There was a significant reduction in the composite outcome mortality/need for extracorporeal life support. Raw 
mortality was not different between the two arms
@ In addition to these outcomes, there was a trend for a clinically less severe respiratory distress
ECMO extra-corporeal membrane oxygenation, PPHN persistent pulmonary hypertension of the neonate, RDS neonatal respiratory distress syndrome (hyaline 
membrane disease)
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multiple benefits in doing so. For instance, oxygenation 
or ventilation metrics as well as lung mechanics param-
eters are repeated measures that lend themselves to 
multilevel (mixed effects) modeling. This will increase 
statistical power, which may be very important when 
studying particular populations in explanatory trials. This 
is also consistent with a personalized medicine approach 
as described above. Last but not least, multilevel mod-
eling/trajectory analysis may adjust for the presence of 
other influencing factors such the availability of extra-
corporeal life support or other co-interventions.
Discussion
Summary of the problem
It is clear that the current perspective of surfactant ther-
apies for PARDS and NARDS was biased by significant 
trial flaws as well as lack of cross-disciplinary aware-
ness and knowledge of ARDS pathobiology. Despite the 
importance of this subject, there has not been any con-
sensus statement  so far. As a consequence, trials have 
been initiated by different investigators, mainly without 
industry support or regulatory agencies contribution 
and without a coordination strategy. Meanwhile biologi-
cal knowledge on surfactant and ARDS was increasing. 
Research in this field is difficult and will still present 
practical and logistical issues; however, the four recom-
mendations represent a helpful tool. In fact, a consensus 
statement is important to put the knowledge in perspec-
tive, increase cross-disciplinary awareness and avoid 
errors from the past.
It is important to recall the history that led to these 
errors: surfactant replacement for RDS was preclinically 
and clinically tested for the first time in 1972 and 1980, 
respectively [73, 74]. At that time, RDS and ARDS were 
considered the two forms of respiratory distress exclu-
sively typical of neonates and adults. As time has passed, 
it became apparent that ARDS was also occurring in chil-
dren [75]. Meanwhile, due to improvements in perinatal 
care, the limit of viability has decreased so infants with 
RDS were more and more premature. Soon it has been 
realized that not all neonates with RDS responded to sur-
factant replacement with similar effectiveness [76] and 
so the existence of NARDS had been hypothesized [77]. 
Finally, PARDS and NARDS have been officially recog-
nized with age-specific definitions modeled on the Berlin 
criteria [3], although earlier ARDS definitions were also 
applied on  children [78]. The first attempts to treat 
PARDS with surfactant have shortly followed the enthu-
siasm of pediatricians using surfactant for RDS [79, 80]. 
Similarly, surfactant administration was tried for a num-
ber of neonatal ‘ARDS-like’ disorders (such as meconium 
aspiration syndrome, pneumonia, sepsis-related res-
piratory failure) [76]. However, these studies have been 
performed without: (1) clear definition of PARDS and 
NARDS, (2) key concepts of pathobiology and (3) clear 
drug development pathway.
Clinical implications of biological research
Exogenous surfactant may be quickly inactivated and/
or damaged by phospholipases: [81] commercially avail-
able surfactants do not contain crucial molecules pro-
viding anti-inflammatory or phospholipase-inhibitory 
activity, such as surfactant protein-A and -D or dioleoyl-
phosphatidylglycerol (DOPG), and this may obviously 
reduce their efficacy [82, 83]. Club Cell secretory pro-
tein [84], human-recombinant surfactant protein-D [85], 
Nf-KB pathway inhibitors [86], DOPG [87] and varesp-
ladib [88, 89] are only some example of drugs that might 
fill this gap, protect surfactant and enhance its activity, 
while decreasing inflammation. Surfactants engineered 
to be more resistant to inactivation might also achieve 
the same objectives. While these molecules have not yet 
reached clinical use, it is not surprising that budesonide, 
a well-known synthetic steroid, had been administered 
using surfactant as carrier. This gave promising results in 
neonates with NARDS [90]. Also, budesonide decreases 
the expression of secretory phospholipase A2 [91] and 
has a clinically significant anti-inflammatory effect in 
preterm neonates at risk of broncho-pulmonary dyspla-
sia [92]. Other surfactant-injuring agents have been well 
characterized in ARDS patients, and surfactant replace-
ment might at least partially counterbalance the reduc-
tion of endogenous surfactant biophysical activity [23]. 
This could be measured at the bedside to personalize 
the dosing  [47, 64]. In time, our knowledge about exoge-
nous surfactant has increased and now we know that not 
all surfactant preparations are equal. Phospholipid profile 
and protein content are important for the clinical efficacy 
in neonates with RDS [26, 93], and it is likely that these 
characteristics would be relevant also in patients with 
PARDS and NARDS [23].
Accuracy and difficulty of clinical trials design
Surfactant trials in PARDS and NARDS have not fol-
lowed a clear drug development pathway, so far. Dose 
ranging trials are still lacking due to bias in funding alleg-
edly ‘definitive studies.’ This is likely the main difficulty 
to design the adequate clinical trial. Others factors to be 
accurately considered are lung size and aeration, presence 
of phospholipases and other surfactant-injuring agents, 
timing of administration, ventilatory policy, resistance 
of surfactant to inactivation and presence of molecules 
enhancing its activity [88, 89, 94, 95]. Moreover, sur-
factant delivery is a complex physical phenomenon: any 
viscous fluid flowing over a surface leaves a coating film 
that increases in thickness as shear viscosity increases. 
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Coating the conducting airways significantly reduces the 
amount of instilled surfactant really reaching the alveoli 
(i.e., the ‘coating cost’): the instilled volumes must be 
above the coating cost to deliver sufficient surfactant to 
the alveoli, and modeling studies show that surfactant 
doses trialed so far have overcome the coating cost only 
for neonates, but not for older patients [56]. This issue is 
extremely important, since too low doses may lack of effi-
cacy, but too high doses may theoretically affect lung tis-
sue inflammation and antibacterial defenses [96, 97].
Surfactant trials published so far have also quite differ-
ent key features, and this made data aggregation difficult, 
especially for pediatric patients. Only recently, a multi-
center study led to definition of sharing criteria to admin-
ister surfactant in PARDS as compassionate therapy [98]. 
Currently ongoing explanatory trials recruit homogene-
ous populations of infants with bronchiolitis-induced 
PARDS [60, 99]. These are examples of a correct step on 
the drug development pathway for a particular subgroup 
of patients.
The administration technique should also be deeply 
studied in order to ensure the best alveolar delivery. 
Bolus or broncho-alveolar lavage with diluted surfactant 
solutions may be used: the latter might be particularly 
efficacious in direct (primary) PARDS and NARDS [100, 
101]. However, the technique is invasive and optimized 
surfactant bolus might provide equally significant ben-
efits at least in some cases.
An adequate clinical research project should be based 
on recent pathobiology concepts and should start from 
finding the best dose and administration schedule/tech-
nique. Then, a trial enrolling direct (primary) PARDS or 
NARDS should be designed targeting meaningful clinical 
outcomes but also physiopathological and/or biological 
or biophysical measures. Enrolled patients should be as 
more homogeneous as possible, not only for the ARDS 
type but also for the other aforementioned factors.
Conclusions
We advocate for well-designed preclinical and explana-
tory clinical studies to investigate the use of surfactant for 
PARDS and NARDS. Given the accumulating knowledge 
on ARDS biology, it is likely that surfactant therapies 
might be beneficial for PARDS and NARDS. Moreover, 
there is wide room for improving these therapies with 
the addition of drugs enhancing surfactant activity and/
or reducing lung inflammation. It is also likely that previ-
ous inconsistent results would have been due to our lack 
of knowledge and misleading study designs. This field is 
an example of how preclinical knowledge can inform the 
clinical research pathway and how explanatory trials are 
needed to prevent losing promising therapies.
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